Finnrick, an independent testing programme, publishes 2 assays for DMV Peptides, and all 2 that it grades met its Purity focus threshold (at least 99.5% purity, no more than 35% dosage deviation). Most recent assay 20 May 2026.
DMV Peptides listed by Finnrick as "Trading". Source: Finnrick, https://www.finnrick.com/vendors/dmv-peptides.
Listed in the Finnrick vendor directory. Not yet tested.
DMV Peptides is listed as active. Tracked by Finnrick. No test data available yet.
No independent third-party assay is on file for DMV Peptides, and its storefront did not respond when we last tried to read it. An untested vendor has not failed a test — this is an absence of evidence, not evidence against it.
| Product | Assays | Result |
|---|---|---|
| Retatrutide | 2 | 2 passed, 0 failed |
Source: Finnrick, as published 2026-08-09. Pass and fail are Finnrick's classification against its own threshold, not ours.
| Status | Active |
|---|---|
| Vendor type | Research-use supplier |
DMV Peptides is listed as active and we hold 2 Finnrick assays (2 passing, 0 failing its purity threshold). That is evidence about the batches that were tested or published, not a guarantee about the vial you receive.
Yes. Finnrick, an independent testing programme, publishes 2 assays for DMV Peptides, and all 2 that it grades met its Purity focus threshold (at least 99.5% purity, no more than 35% dosage deviation). Most recent assay 20 May 2026.
Popular peptides: Semaglutide, Tirzepatide, Retatrutide, BPC-157, CJC-1295, Ipamorelin.
Other reviewed vendors: DNLab Research Peptides Review, Domestic Peps Review, Dr Peptides Review.